^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lymphoma

    Related cancers:
    16h
    Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma. (PubMed, Blood Adv)
    Conditioning was based on total body irradiation (TBI) in 30 patients and on chemotherapy in 27 patients, mainly with reduced-toxicity conditioning (RTC; Treosulfan, Fludarabine, and Thiotepa). Our data support the use of TBI-free conditioning and suggest improved outcomes with unrelated donors receiving ATLG prophylaxis. NCT00317408.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    fludarabine IV • thiotepa • Grafapex (treosulfan)
    16h
    FDG PET/CT in a Case of Primary Tracheal ALK-Negative Anaplastic Large Cell Lymphoma. (PubMed, Clin Nucl Med)
    The tumor was located in the lower tracheal wall and showed intense activity. A follow-up FDG PET/CT after 8 cycles of chemotherapy showed complete resolution of the tumor.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK negative
    17h
    GLOBRYTE: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=182, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2027 --> Mar 2028 | Trial primary completion date: Feb 2027 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    17h
    Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 30
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    22h
    Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine. (PubMed, Discov Oncol)
    This review systematically summarizes the core mechanisms by which EBV contributes to lymphoma pathogenesis and evaluates the breakthroughs and challenges of current therapeutic strategies. It also outlines the future directions of precision medicine, based on multi-disciplinary integration, to enhance the understanding of the molecular pathology of EBV-associated lymphomas and optimize personalized treatment.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    1d
    XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells. (PubMed, Hematology)
    Cell lines representing DLBCL subtypes were treated with varying concentrations of the XPO1 inhibitor selinexor (XPO1i), cisplatin (CDDP), and oxaliplatin (OXA), alone or in combination. In OCI-Ly8 and OCI-Ly1 cells, OXA alone inhibited phosphorylation of AKT and mTOR while increasing phosphorylation of JNK, ATM, and p53, and expression of γH2AX; these effects were potentiated by the combination of XPO1i and OXA. XPO1 inhibition enhances platinum-induced cytotoxicity in GCB-DLBCL, supporting clinical evaluation of XPO1i-platinum combinations as salvage therapy.
    Journal • IO biomarker
    |
    XPO1 (Exportin 1)
    |
    cisplatin • oxaliplatin • Xpovio (selinexor)
    1d
    Venetoclax and Decitabine in R/R T-ALL (clinicaltrials.gov)
    P2, N=28, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • decitabine
    1d
    CS22-03: Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (clinicaltrials.gov)
    P=N/A, N=30, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed
    Trial completion
    1d
    PBCAR0191-01: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P1, N=135, Recruiting, Imugene Limited | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • azercabtagene zapreleucel (PBCAR0191)
    1d
    Aquarius: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P=N/A, N=550, Recruiting, Tempus AI | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=93, Completed, Memorial Sloan Kettering Cancer Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Matulane (procarbazine hydrochloride)